Cargando...
Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
Lorlatinib treatment should be positively considered even for patients with ALK‐positive NSCLC with severe neurocognitive disturbance and poor performance status due to CNS metastases, including leptomeningeal carcinomatosis.
Gardado en:
| Publicado en: | Clin Case Rep |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077276/ https://ncbi.nlm.nih.gov/pubmed/33936630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3927 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|